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Abstract Nitrous oxide is a gas inhalation agent that has
a long history of administration in procedures requiring
analgesia and sedation. Although use may be limited by
patient condition, patient comorbidities, and appropriate
scavenging equipment, nitrous is a proven and safe tool for
use in many health care settings—from the dental office to
the operating room to the emergency department.
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Introduction: Procedural Sedation and Analgesia
(PSA)
Physicians and medical care providers in general are
charged with promoting health, as well as diagnosing and
managing illness. The breadth of knowledge and skills
required to manage multiple medical conditions, including
emergency conditions, is vast and ever changing. In caring
for our patients, knowledge and skill specifically in the
management of pain and providing sedation are
indispensable.
Procedural sedation and analgesia (PSA) has become an
integral tool for the physician in the diagnosis and man-
agement of disease processes and injuries. PSA is a tech-
nique utilized frequently by both anesthesiologist and non-
anesthesiologists and involves the administration of a
sedative or dissociative agent with or without an analgesic
agent to induce a state that allows the patient to tolerate a
painful and/or noxious procedure while maintaining spon-
taneous cardiovascular and respiratory functions. The
levels of sedation for PSA can be divided into five different
sub-groups [1] (Table 1).
For example, PSA is frequently utilized in the treatment
of the pediatric population to reduce the fear and anxiety as
well as the pain experienced by children prior to and during
procedures.
Characteristics of the ideal PSA agent would include
(1) providing both sedation and analgesia,
(2) having a quick onset of action and rapid recovery
upon discontinuation,
(3) preserving the cardiovascular and respiratory status of
the patient,
(4) imparting an amnestic quality.
Nitrous oxide possesses many of these properties, mak-
ing it an ideal agent for PSA in the emergency department,
as well as other medical arenas. In this article, we will
review the history, mechanism of action, administration,
applications, as well as the adverse effects of nitrous oxide.
History
Nitrous oxide (chemical structure: N2O) was first isolated
in 1772 by the English chemist Joseph Priestly and was
originally given the name ‘‘dephlogisticated air’’ [2]. It was
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not until nearly two decades later that the Cornish chemist
Humphry Davy would arrive at the Pneumatic Medical
Institution in Bristol to conduct experiments on himself
with N2O and discover its analgesic properties [3]. In 1800,
he further went on to publish a book describing its potential
role in medicine:
As nitrous oxide in its extensive operation appears
capable of destroying physical pain, it may probably
be used with advantage during surgical operations in
which no great effusion of blood take place [4].
However the use of N2O for surgeries never took hold
and it was instead relegated for recreational use as
‘‘laughing gas’’ into the early 19th century. It was briefly
reintroduced into medical practice in 1844 when the
American dental surgeon Horace Wells utilized the appli-
cation of N2O to alleviate pain during tooth extraction.
After a highly publicized failed experiment was conducted
at the Massachusetts General Hospital, it then disappeared
from the medical arena and was quickly overshadowed by
the introduction of other notable inhaled anesthetics such
as ether and chloroform [5].
Finally in 1863, almost a century after its initial discovery,
Gardner Quincy Colton established the use of N2O in den-
tistry, solidifying it as a popular tool for painful dental pro-
cedures. Shortly thereafter, the use of N2O expanded into
other medical fields, most notably obstetrics and surgery [6].
Since then, the administration of N2O has undergone
numerous advances, increasing its safety and reliability.
While the use of N2O as an adjunctive induction agent for
anesthesia in dentistry and the operating room has been well
established, it was only relatively recently that the use of
N2O has emerged as a valuable tool for PSA in the emer-
gency department/acute care setting.
Mechanism of Action
Nitrous oxide is a colorless and mostly odorless gas that is
stable at room temperature and ambient pressure. It is heavier
than air. When inhaled, it has been demonstrated to have both
anesthetic and analgesic properties. While the exact mech-
anism of action of N2O remains to be completely elucidated,
there are several existing theories that describe how it exerts
its effects. Unlike other well-known anesthetics, such as
propofol and etomidate, which act directly on the inhibitory
c-aminobutyric acid (GABA) type A receptors, N2O has
been shown to modulate a different target. The prevailing
theory suggests N2O provides its anesthetic properties
through the non-competitive inhibition of the excitatory
NMDA subtype glutamate receptors [7].
In contrast, the mechanism by which N2O exerts its
analgesic effects is much better understood. Research
indicates that N2O induces endogenous opioid peptide
release by binding to opioid receptors located in the peri-
aqueductal gray matter and noradrenergic of the brainstem.
This results in the release of opioid in the brainstem, which
in turn inhibits the GABA neurons thereby removing the
tonic inhibition on the descending noradrenergic inhibitory
pathways. This dis-inhibition of the noradrenergic neurons




Patient response the patient responds normally to verbal commands although cognitive functions and coordination
may be impaired
Cardiovascular functions remain unaffected
Respiratory functions remain unaffected
Moderate sedation Patient response the patient has a depressed state of consciousness but can respond purposefully to verbal commands
with or without gentle tactile stimulation. This does not include reflexive withdrawal from a painful stimulus
Cardiovascular functions remain unaffected
Respiratory functions remain unaffected
Dissociative sedation Patient response the patient is in a trance-like cataleptic state that is characterized by profound analgesia and amnesia
Cardiovascular functions remain unaffected
Respiratory functions remain unaffected
Deep sedation Patient response the patient has a depressed state of consciousness and is not easily arousable but responds
purposefully after repeated or painful stimulation
Cardiovascular functions usually remain unaffected
Respiratory functions may be impaired
General anesthesia Patient response the patient has a loss of consciousness and is not arousable even with painful stimulation
Cardiovascular functions may be impaired
Respiratory functions are often impaired and the patient typically requires positive-pressure ventilation support
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in the brainstem modulates nociception by releasing nore-
pinephrine into the spinal cord thereby inhibiting pain
signaling [8, 9].
The potency of nitrous oxide is dependent on the mini-
mum alveolar concentration (MAC). The minimum alveolar
concentration of an inhaled anesthetic is defined as the
expired concentration or dose of an inhalational agent
required to suppress movement in 50 % of patients in
response to a surgical stimulus. Thus the lower the MAC, the
more potent the agent. There are several factors that can
influence the MAC of a particular agent such as age, addition
of adjunctive medications, and pre-existing patient condi-
tions. The MAC50 is 104 % for N2O, thus making it a poor
single agent for general anesthesia. However, when admin-
istrated at sub-MAC concentrations in combination with an
analgesic, it acts as an effective anxiolytic ideal for PSA [10].
Administration
Nitrous oxide is typically stored under 750 psi as a vapor
overlying a liquid in a color-coded tank; in the United
States, the standard tank color is blue. N2O is neither
flammable nor explosive, but it is capable of supporting
combustion and therefore open flames should not be
allowed near the storage tanks.
N2O can be administered as a 30–70 % N2O–oxygen
mixture by a demand-valve mask or mouthpiece held by the
patient (self-administration). It is typically administered as a
50–50 % or 70–30 % N2O–oxygen mixture, with at least
30 % oxygen to avoid hypoxemia. A 30 % N2O concentra-
tion may be less than effective for PSA, especially in chil-
dren. Administration of high concentrations of N2O
(50–70 %) for PSA has been shown to be safe with no sig-
nificant difference in the rate of adverse events between the
two groups [11].
Although N2O is considered a mostly odorless gas, the
tubing and mask that comprise the delivery system often
times have an unpleasant odor that is disturbing to pediatric
patients. Therefore, the common form of practice is to coat
the inside of the mask with a liquid that produces a
vaporized scent that is pleasing to the child, such as
strawberry or bubblegum.
Benefits of N2O for PSA
There are many attractive qualities of N2O that make it an
appealing agent for PSA, particularly in the pediatric
emergency department [12]:
(1) N2O is known to be an excellent anxiolytic that can
be administered without the need for intravenous
access. Particularly in the pediatric population,
sometimes the means to a cure (e.g. injection of an
anxiolytic) can often times be viewed as worse than
the actual cure itself (e.g. suturing a simple forehead
laceration). Thus, in caring for a fearful toddler, N2O
may be a far superior choice when compared to other
anxiolytics at our disposal, particularly those that
require intravenous access or irritating intranasal
administration. N2O even has advantage over oral
medications that typically have a delayed onset of
action.
(2) Due to its low solubility in the blood (blood–gas
partition coefficient = 0.47), this allows for rapid
onset of action in the brain (30–60 s) as well as rapid
clearance through the lungs shortly after discontinu-
ation [13]. In a busy emergency department, decreas-
ing the length of stay for patients requiring procedural
sedation for painful procedures is of benefit.
(3) It provides a minor amnestic effect. Children who
have been sedated with N2O often have little recol-
lection of the painful elements of the procedure [14].
(4) It has a long history of having an excellent safety
profile with few reported cases of adverse events. The
most frequently reported adverse reaction is nausea
and vomiting. There are few reported cases of serious
injury from appropriate N2O administration. There
are no reported allergies to N2O and it has not been
shown to be associated with malignant hyperthermia
[15]. There have been several case reports of nitrous
oxide-induced myelopathy [16], polyneuropathy [17,
18], and seizure activity [19] reported. Some of these
cases are associated with higher exposures and/or
abuse.
(5) It is easily transportable. The units that are manufac-
tured for supplying nitrous oxide in the emergency
department are small and portable making it easy to
store and transport between patient rooms.
(6) The use of N2O at PSA concentrations has been
shown to have minimal effects on the hemodynamic
status, spontaneous respiration, cerebral blood flow,
and protective airway reflexes of the patient [13]. This
makes it a remarkably safe drug to use in emergency
situations where patients may already present with
underlying physiologic compromise.
(a) Cardiovascular Although N2O has been
reported to decrease myocardial contractility
in vitro, it also simultaneously stimulates cate-
cholamine release by the sympathetic nervous
system thereby leaving cardiac output, blood
pressure, and heart rate relatively unchanged
in vivo.
CO = SV 9 HR
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where CO is cardiac output, measured in L/min
SV is stroke volume, measured in L/beat, and
HR is heart rate, measured in beats/min.
(b) Respiratory N2O has the effect of increasing the
respiratory rate and decreasing the tidal volume
thereby maintaining relatively unchanged min-
ute ventilation.
_V ¼ VT  f ;
where _V is minute ventilation, measured in
L/min, VT is tidal volume, measured in L, and
f is respiratory rate, measured in breaths/min.
(c) Cerebral blood flow N2O causes a small increase
in cerebral blood flow and volume thereby
producing a mild elevation in intracranial
pressure. It may also slightly increase cerebral
oxygen consumption.
CBF = CPP/CVR and
CPP = MAP - ICP
where CBF is cerebral blood flow, CPP is cerebral
perfusion pressure, CVR is cerebrovascular
resistance, MAP is mean arterial pressure, and
ICP is intracranial pressure.
Applications of Nitrous Oxide
Dentistry
As mentioned earlier, N2O was first popularized in the 1860s
as an anxiolytic and analgesic tool for performing simple
dental procedures such as tooth extraction. Remarkably, it
has endured through time and is still used in modern dentistry
as one of the most frequently employed inhalational seda-
tives for pediatric dental procedures. The benefits of N2O in
dentistry are threefold: (1) anxiolysis, (2) depressed gag and
swallow reflexes, and (3) analgesia [15]. Nitrous oxide is
more commonly used today as an adjunctive anxiolytic, as
there is a wide variety of oral sedative medications that can
be taken prior to arrival for their dental procedure. In addi-
tion, pre-medication with oral sedatives such as midazolam
has been shown to increase the depth sedation when com-
bined with N2O during the procedure [20].
Operating Room
Surgeons and anesthesiologists were also among the first to
utilize inhalational gases for general anesthesia in patients
undergoing surgical operations. Nitrous oxide was one of
the first inhalational anesthetics observed to be beneficial in
the operating room. However, in modern day use it has
taken a lesser role as compared to other more potent
inhalational anesthetics. However, it is still widely used in
operating rooms today for several reasons: (1) it does not
require IV access, (2) it has a rapid on/off effect, (3) it is
relatively inexpensive as compared to other inhalational
anesthetics, and (4) it does not have significant emergence
issues [12].
Emergency Department
Many procedures that are commonly performed, frequently
in the emergency department, have a tendency to incite a
high level of anxiety, particularly in the pediatric popula-
tion. Addressing pain and anxiety is not only benevolent
(for both the patient and parents) but also necessary to help
facilitate the safe and efficient execution of various emer-
gency department procedures.
Several studies have examined the efficacy and safety
of N2O in PSA. These studies look at the use of N2O
during PSA for a variety of procedures ranging from
wound examination to minor surgery. In a review article
published in 2013, seven out of eight articles that
examined the use of N2O in PSA noted favorable out-
comes [21]. The one article that did not show a favor-
able outcome had a significant percentage of patients
(45 %) who reported pain scores greater than 50 (on a
scale of 0–100). The same study, however, also reported
a high percentage (93 %) of parental satisfaction with
the procedure [22].
PSA with N2O has also been examined in the setting of a
single specific procedure. N2O has been demonstrated to be
an extremely effective anxiolytic; however, due to its low
potency as an analgesic agent, it is rarely used as a single
agent. Often times, it is paired with either a local nerve
block or systemic analgesia to provide maximum pain
relief before and/or during a procedure.
Venipuncture
Several studies have examined the efficacy of N2O for
anxiolysis and analgesia for venipuncture. These studies
have shown that it is both effective as a single agent [23]
and in combination with topical analgesic creams such as
EMLA [24, 25].
However, in a cost-effectiveness study comparing sev-
eral methods of analgesia for intravenous cannulation,
needle-free jet injection of lidocaine had the best cost-ef-
fectiveness ratio, better than N2O [26]. Therefore, the
widespread use of N2O solely for the purpose of
venipuncture may not be as favorable in the emergency
department.
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Laceration Repair
Laceration repair is a frequent reason for pediatric emer-
gency department visits. Wound closure is not only cos-
metically beneficial, but also helps accelerate the healing
process and prevent further wound contamination. There
are several studies that examine the efficacy of N2O for
primary wound closure [27–30]. They conclude that N2O is
not only effective at decreasing anxiety [30] and pain [28],
but that N2O is actually preferable over other sedatives
such as oral midazolam [29] or intravenous ketamine [27]
given its fast induction time and quick recovery time.
Furthermore, N2O was shown to have less adverse effects,
such as nausea and vomiting, as compared to oral mida-
zolam [29] or intravenous ketamine [27].
Fracture Reduction
Fracture reduction is one of the most painful procedures
commonly performed in the Pediatric Emergency Depart-
ment. Even under the best PSA conditions, children often react
to the aggressive reduction maneuvers required to realign
fractured bones. Nitrous oxide has been demonstrated to be
safe to administer, although less effective as a single agent for
analgesia during fracture reduction [31]. However, in com-
bination with a hematoma block, N2O has been shown to be
effective in providing adequate PSA for fracture reductions
[32, 33]. Furthermore, in one study comparing N2O ? he-
matoma block versus ketamine ? midazolam, N2O ? he-
matoma block was shown to have fewer adverse effects and a
significantly quicker recovery time [33].
Other
There have been several additional studies that have
examined the use of N2O in the setting of other painful and/
or uncomfortable procedures. As may be reasonably
inferred by its efficacy for intravenous cannulation, N2O
has also been shown to provide adequate PSA for other
emergency department procedures that involve needle
punctures such as intra-articular injections [34] and lumbar
puncture [35]. Nitrous oxide also has been shown to be
effective in reducing pain and anxiety during limited burn
debridement [36]. Other procedures that have been suc-
cessfully performed with the aid of N2O include abscess
drainage, foreign body removal, urinary catheterization,
wound examination, and joint aspiration [21].
In addition to PSA, N2O may also be utilized to manage
pre-existing pain. There have been only a few studies that
have examined the use of N2O for pain management. One
study demonstrated that N2O may have some benefit for
the short-term management of migraines [37] as well as to
enhance the analgesic effect of morphine in vaso-occlusive
crisis in the sickle cell patient [38].
To our knowledge, there have not been any published
papers examining the use of N2O for uncomfortable or
unsettling examinations that may need to be urgently
conducted in the emergency department such as child
abuse exams, ophthalmological exams, and diagnostic
imaging. However, given that these exams are mostly
anxiety provoking rather than painful, administration of
N2O may be beneficial in facilitating the prompt execution
of these types of examinations while minimizing anxiety in
the pediatric patient.
Pre-hospital Setting
Many traumatic patients arrive to the emergency depart-
ment via pre-hospital emergency medical services (EMS).
In addition to stabilizing the patient, part of the EMS
objective is to provide initial pain management. The use of
N2O has been proposed and studied in the pre-hospital
setting. In a double-blind multi-center study conducted in
France, the investigators were able to show that pre-hos-
pital administration of a fixed 50:50 ratio of N2O:O2 was
effective in management of traumatic pain in the field [39].
However, further studies are needed to further assess the
safety of its use in the pre-hospital setting.
Side Effects
The administration of nitrous oxide is relatively safe, with
few patients experiencing any adverse events. Some of the
most commonly reported negative side effects of N2O
include vomiting, nausea, dizziness, headache, tingling,
and euphoria [14]. The risk of nausea and vomiting after
N2O administration increases with the duration of sedation
[40]. However, in cases where N2O was administered for
\15 min, the rate of nausea and vomiting were 1 to 1.6 %
[41]. Furthermore, the fasting status of the patient prior to
the procedure does not appear to have a significant effect
on the frequency of adverse events [42].
There are very few instances of major complications
reported with the use of N2O, such as oxygen desaturation,
aspiration, or bradycardia. The rate of major events was
mainly affected by (1) age and (2) the use of adjunctive
medications such as benzodiazepines [43]. However,
despite its good track record, there was a case report of
laryngospasm and with apparent aspiration with adminis-
tration of N2O as a single agent published in 2015. The
authors highlight the fact that although generally safe, N2O
should still be administered in settings where airway
emergencies can be quickly managed [44]. Diffusion
hypoxia can occur with the use of nitrous oxide especially
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when self-administration of the nitrous oxide ceases or at
the end of the procedure. Diffusion hypoxia refers to the
decrease in alveolar oxygen tension when room air is
inhaled at the conclusion of nitrous oxide administration
due to nitrous oxide diffusing out of the blood and diluting
the alveolar oxygen. This is why continuous pulse oximetry
is recommended when using nitrous oxide. [24] (Table 2)
Contraindications
As mentioned earlier, N2O has a low solubility in the blood
and this characteristic accounts for its rapid onset of action
in PSA. However, essential to the evaluation of its safety, it
is important to note that N2O is 35 times more soluble than
nitrogen (the principal component of air) in blood. Thus,
when N2O is inhaled, it will diffuse into air-filled spaces
faster than nitrogen can be reabsorbed into the blood-
stream. In enclosed cavities of the body, this may result in
the rapid expansion of gas resulting in injury from
increasing pressure [13]. Examples of conditions where
this may be of concern include chronic obstructive pul-
monary disease or any other bullous or emphysematous
lung disease including advanced cystic fibrosis, pneu-
mothorax, pneumocephalus, intraocular air bubbles, middle
ear effusions, air embolism, bowel obstruction, and
decompression sickness. The magnitude of the pressure
increase and volume expansion caused by N2O depends on
several factors: (1) the Pa of nitrous oxide, (2) blood flow
to the air-filled cavity, and (3) duration of exposure.
Nitrous oxide has been demonstrated to increase the vol-
ume of a pneumothorax [45]. As demonstrated in an animal
model, administration of 75 % N2O doubles the volume of
a pneumothorax in 10 min [10]. However, another animal
study from 1995, though showing an increase in pneu-
mothorax size, showed essentially no clinical effect [45].
(Table 2).
Toxicity
The most notable toxicity reported from the inhalation of
nitrous oxide is the irreversible inactivation of cobalamin
(vitamin B12). Vitamin B12 serves as an important co-en-
zyme (Co-B12) in two metabolic processes in the human
body: (1) methylmalonyl-CoA-mutase and (2) methionine
synthase. Inhibition of the methionine synthase enzyme
results in decreasing levels of hematopoietic functions and
increasing levels of homocysteine concentrations [46, 47].
Thus, chronic use of nitrous oxide can theoretically result in
hematologic problems, bone marrow suppression, and CNS
toxicity. However, despite its inhibitory effect on vitamin
B12, with limited exposure (up to 8 h), there has been no
clinical sign of megaloblastic anemia seen in pediatric
patients undergoing lengthy surgical procedures [48].
Given the potential effects from long-term exposure to
nitrous oxide, hospital personnel who work in areas where
nitrous oxide is being utilized are in theoretic danger.
Environmental exposure to nitrous oxide in the emergency
department is one reason for scavenger devices and proper
ventilation to be installed where N2O is being utilized. In
areas where N2O is administered with proper a scavenger
device, 0 ppm of N2O is detected in the surrounding
environment [49].
Abuse Potential
The term ‘‘laughing gas’’ is a common layman’s term for
nitrous oxide, given its ability to create a sense of euphoria
in the user. In addition, as noted earlier, it has an opioid-
like effect, which accounts for its analgesic properties.
Nitrous oxide can be found in a variety of readily available
items such as whip-cream dispensers. There are case
reports of myeloneuropathy involving the posterior and
lateral columns (aka: subacute combined degeneration of
the spinal cord) [50, 51] and a fatality [52] from inhalation
of nitrous oxide from whip-cream dispensers.
Unfortunately, with the use of nitrous oxide in the
emergency department, comes the potential for abuse. In
1995, there was a published case report of a hospital
worker who had access to the hospital nitrous oxide
Table 2 Nitrous oxide: side effects and contraindications







Contraindications—any ‘‘trapped air’’ in the body
Examples of ‘‘trapped air’’ include
Pneumothorax







Bullous or emphysematous lung disease (such as advanced cystic
fibrosis)
There has been a recent report of one case report of laryngospasm
with aspiration with the administration of nitrous oxide as a sole agent
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supply and died from asphyxia due to unauthorized N2O
inhalation [53]. Such cases highlight the importance of
robust security procedures and equipment when storing and
utilizing nitrous oxide.
Conclusions
Although limited as solely an anesthetic agent, nitrous
oxide remains a versatile and useful tool for treatment of
pain and anxiety from the operating room to the dental
office to the emergency department. Its efficacy and safety
is well established, particularly in the pediatric emergency
department, where its use alone or in combination with
other agents can help facilitate performing painful and/or
anxiety-provoking procedures such as the reduction of
fractures and repair of lacerations.
Its use is limited by the ability to provide adequate
ventilation/scavenging, as well as the ability to appropri-
ately secure the agent and its delivery equipment to prevent
abuse. As with any agent, there exists the potential for
harm with its use. Notably, when used for PSA in the
emergency department, these risks are low, but increase
with increased duration of use, increased dose, concurrent
use of other medications, and with complicating host
factors.
Potential future applications of N2O, following further
study, may include treatment of pain in EMS patients while
still in the pre-hospital setting.
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